By Denny Jacob
Relmada Therapeutics lost more than two-thirds of its market value early Wednesday after the biotechnology company said a treatment for major depressive disorder would likely fail to meet its primary goal in a trial it deemed futile.
Shares of Relmada dropped 77% to 64 cents in premarket trading. The stock already was down by about a third since the start of the year, as of Tuesday's close.
The Coral Gables, Fla., company said an interim analysis by an independent data monitoring committee found the treatment was unlikely to meet the primary endpoint with statistical significance in a Phase 3 study.
The treatment, REL-1017, was being evaluated as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants.
Relmada said no new safety signals were reported.
"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program," Chief Executive Sergio Traversa said.
Relmada said it will focus on the development of a treatment for metabolic disease, REL-P11, adding the company was well-capitalized with about $54.1 million in cash and cash equivalents as of Sept. 30.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 04, 2024 08:40 ET (13:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。